Todd Punim
Low Vision Rehabilitation · Monroe, NYNPI 1497829600
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,501 of the $4,437 with a category attached, or 78.9%. 20 manufacturers reported payments, led by Coopervision Inc. at 29.9% of the total. Reporting peaked in 2023 at $860 and has fallen 53.8% since, to $397 in 2025. Among low vision rehabilitation clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coopervision Inc.$1K
- Alcon$1K
- Bausch & Lomb Americas Inc.$338
- AbbVie$315
- Sun Pharmaceutical Industries Inc.$186
- Tarsus Pharmaceuticals, Inc.$157
- plus $865 from 14 others
What the payments were for
- Speaking & faculty fees$91721%
- Food & beverage$3,50179%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coopervision Inc. | 28 | $1,329 |
| Alcon | 40 | $1,247 |
| Bausch & Lomb Americas Inc. | 17 | $338 |
| AbbVie(2 entities) | 8 | $315 |
| Sun Pharmaceutical Industries Inc. | 10 | $186 |
| Tarsus Pharmaceuticals, Inc. | 5 | $157 |
| Sight Sciences, Inc. | 3 | $136 |
| Novartis | 6 | $123 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $123 |
| Johnson & Johnson Vision Care, Inc. | 6 | $122 |
| Optos, Inc. | 1 | $79 |
| Visioneering Technologies, Inc. | 6 | $74 |
| Aerie Pharmaceuticals, Inc. | 4 | $66 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Spark Therapeutics, Inc. | 1 | $21 |
| LKC Technologies, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Amgen | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $17 |
| Glaukos Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,437 in reported general payments places this provider in the 95th percentile of 20 low vision rehabilitation providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 24 | $1,359 |
| Latanoprost | 73 | $978 |
| Prednisolone Acetate | 17 | $479 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 41 | $437 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 26 | $409 |
| Timolol Maleate | 19 | $29 |
Paid to pharmacies, not to this prescriber.
Other low vision rehabilitation in Monroe
- Lawrence MillerMonroe$50
- Kristin ProtosowRonkonkoma$4K
- Tracy SheedyRed Hook$3K
- Howard FishmanNew Hyde Park$3K
- Jeffrey CalhounWilliamsville$3K
- John RundquistAmherst$2K
- Charles HollanderNew York$2K
- Emily ChuForest Hills$814
- Robert ChunNew York$448
- Carolyn IhrigFredonia$368
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.